Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 2Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Mouth Neoplasms 1Lymphatic Metastasis 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Histiocytoma, Malignant Fibrous 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Dermatofibrosarcoma 1Cholangiocarcinoma 1Carcinoma 1

Interventions

Cyclophosphamide 13Bevacizumab 9Interleukin-2 8aldesleukin 7Paclitaxel 7fludarabine phosphate 6fludarabine 6Radiotherapy 6Bortezomib 6Thalidomide 5Gemcitabine 5Filgrastim 5veliparib 4sargramostim 4Vincristine 4Trastuzumab 4Prednisone 4Leucovorin 4Doxorubicin 4Biopsy 4vandetanib 3tariquidar 3romidepsin 3pazopanib 3montanide ISA 51 3Topotecan 3Specimen Handling 3Sorafenib 3Sirolimus 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasms × peposertib × Clear all
NCT04092270 2026-05-13

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡